College of Pharmaceutical Science, Zhejiang University, 388 Yuhangtang Road, Hangzhou 310058, PR China.
Biomaterials. 2009 Dec;30(36):6955-63. doi: 10.1016/j.biomaterials.2009.09.008. Epub 2009 Sep 25.
Doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles (DOX-CSO-SA) was synthesized via cis-aconityl bond between the anticancer drug doxorubicin (DOX) and stearic acid grafted chitosan oligosaccharide (CSO-SA) in this paper. The CSO-SA micelles had been demonstrated faster internalization ability into tumor cells. Here, the CSO-SA with 6.47% amino substituted degree (SD%) was used to synthesize DOX-CSO-SA. The critical micelle concentration (CMC) was about 0.14 mg mL(-1). The micelles with 1 mg mL(-1) CSO-SA concentration had 32.7 nm number average diameter with a narrow size distribution and 51.5 mV surface potential. After conjugating with doxorubicin, CMC of DOX-CSO-SA descended; the micellar size increased; and the zeta potential decreased. The DOX-CSO-SA micelles indicated pH-dependent DOX release behavior. The release rate of DOX from DOX-CSO-SA micelles increased significantly with the reductions of the pH for release medium from 7.2 to 5.0. In vitro antitumor activity tests of DOX-CSO-SA micelles against human breast carcinoma (MCF-7) cells and their multi-drug resistant (MCF-7/Adr) cells presented the reversal activity against DOX resistance MCF-7 cells (MCF-7/Adr). The in vivo antitumor activity results showed that DOX-CSO-SA micelles treatments effectively suppressed the tumor growth and reduced the toxicity against animal body than commercial doxorubicin hydrochloride injection.
阿霉素偶联硬脂酸-g-壳聚糖寡糖聚合物胶束(DOX-CSO-SA)通过顺式丙烯酰键合在抗癌药物阿霉素(DOX)和硬脂酸接枝壳聚糖寡糖(CSO-SA)之间合成。CSO-SA 胶束已被证明具有更快的进入肿瘤细胞的内化能力。在这里,使用取代度(SD%)为 6.47%的 CSO-SA 来合成 DOX-CSO-SA。临界胶束浓度(CMC)约为 0.14 mg mL(-1)。CSO-SA 浓度为 1 mg mL(-1)的胶束具有 32.7nm 的数均直径,具有较窄的粒径分布和 51.5 mV 的表面电位。与阿霉素偶联后,DOX-CSO-SA 的 CMC 降低;胶束粒径增大;zeta 电位降低。DOX-CSO-SA 胶束表现出 pH 依赖性 DOX 释放行为。DOX 从 DOX-CSO-SA 胶束中的释放速率随着释放介质的 pH 值从 7.2 降低到 5.0 而显著增加。DOX-CSO-SA 胶束对人乳腺癌(MCF-7)细胞及其多药耐药(MCF-7/Adr)细胞的体外抗肿瘤活性测试显示出对 DOX 耐药 MCF-7 细胞(MCF-7/Adr)的逆转活性。体内抗肿瘤活性结果表明,DOX-CSO-SA 胶束治疗能有效抑制肿瘤生长,降低对动物机体的毒性,优于商业盐酸阿霉素注射液。